Earnings call Advanced Enzymes reported Q3 FY25 consolidated revenue of ₹1,691 million, up 5% YoY and 16% QoQ (adjusted growth 5%). EBITDA rose 3% YoY and 30% QoQ to ₹553 million, with margins at 33%.

Earnings call Advanced Enzyme Technologies reported FY25 revenue growth of 2% YoY and Q4 revenue up 6% YoY. EBITDA margins compressed to 27% in Q4 due to product mix and inventory adjustments.

About Advanced Enzyme Technologies Ltd. Advanced Enzyme Technologies Ltd. engages in the research, development, manufacture, and sale of enzyme products. It offers products for human nutrition, animal ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

On August 8, Advanced Enzyme Technologies reveals figures for Q1. Wall Street analysts expect Advanced Enzyme Technologies will report earnings per share of INR 2.89. Watch Advanced Enzyme ...

On November 2, Advanced Enzyme Technologies will be reporting Q2 earnings. Wall Street analysts expect Advanced Enzyme Technologies will release earnings per share of INR 2.85. Track Advanced Enzyme ...

NetEase Games on Monday released specific dates and time slots during which Chinese children will be permitted to play its video games during the upcoming Mid-Autumn Festival and National Day holidays ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

We've identified the following companies as similar to Advanced Enzyme Technologies Ltd because they operate in a related industry or sector. We also considered size, growth, and various financial ...

* Seeks members' nod to approve related party transaction with JC Biotech Private Limited‍ Source text: Further company coverage: Sign up here. Macro Matterscategory Fed's rate cut revives small ...